An official website of the United States government Here's how you know

U.S. Department of Health and Human Services | National Institutes of Health

Official websites use .gov
A .gov website belongs to an official government
organization in the United States.

Secure .gov websites use HTTPS
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.

PAR-22-200 - Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)

Expired NOSIs

Title	Notice Number	Organization	Release Date	Expiration Date	Activity Code(s)
Notice of Special Interest (NOSI): Discovery and Development of Natural Products to Treat Substance Use Disorders (SUDs)	NOT-DA-25-032	NIDA, NCCIH	Nov 25, 2024	Sep 9, 2025	R01, UG3/UH3, U01, R21
Notice of Special Interest (NOSI): HEAL Initiative: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose	NOT-DA-23-010	NIDA	Sep 28, 2022	Sep 2, 2025	UG3/UH3
Notice of Special interest (NOSI): Medications Development for Stimulant Use Disorders	NOT-DA-22-049	NIDA	Dec 22, 2021	Sep 2, 2022	UG3/UH3

For technical issues E-mail OER Webmaster

Redirect Notice

PAR-22-200 - Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)

Expired NOSIs

Stay Connected

Government Sites

Web Policies and Notices

Site Map